NewsBenzingaBarclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19 Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19 Benzinga 2026.11.06 16:16 (GMT+0) Open on Benzinga Other news Ladenburg Thalmann Maintains Buy on MGE Energy, Raises Price Target to $86.5 Telsey Advisory Group Maintains Outperform on Steven Madden, Lowers Price Target to $50 Telsey Advisory Group Maintains Market Perform on Arhaus, Raises Price Target to $14 Telsey Advisory Group Maintains Outperform on Holley, Lowers Price Target to $4 Telsey Advisory Group Maintains Outperform on Westrock Coffee, Raises Price Target to $13 Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117
